Skip to main content
. 2003 Jul;5(4):297–307. doi: 10.1016/S1476-5586(03)80023-4

Figure 5.

Figure 5

Biodistribution of RAFL-1 antibody in mice bearing orthotopic MDA-MB-231 human breast xenografts. Nu/nu mice bearing MDA-MB-231 tumors in their MFPs were injected intravenously with 50 µg of RAFL-1 antibody. One hour later, their blood circulation was perfused with saline, and tumors and normal organs were harvested and prepared for cryosectioning. VEGFR2 protein was detected by incubating frozen sections with RAFL-1 antibody and appropriate secondary antibody (left column). The RAFL-1 antibody that localized to the vasculature after intravenous injection was detected indirectly by incubating sections with secondary antibody alone (center column). To identify vessels, parallel sections were stained with a pan-endothelial marker, anti-CD31 antibody (right column). Note that the majority of tumor vessels both express VEGFR2 and display localized RAFL-1 antibody. Kidney glomeruli behave likewise. Neither VEGFR2 protein nor localized RAFL-1 antibody was detected on vessels of lung or heart.